NCT01400074View on ClinicalTrials.gov

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib

PHASE3UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Nilotinib, Imatinib

Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily

Trial Locations (1)

137-701

RECRUITING

Seoul St. Mary's Hospital, Seoul

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Seoul St. Mary's Hospital

OTHER